KAPA (Kairos Pharma) Insider Ownership: 10.68 % (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.29
View Full Analysis

What is Kairos Pharma Insider Ownership?

Kairos Pharma KAPA -1.73% 15 Insider Ownership is 10.68 % as of Aug. 22, 2026. GuruFocus rates KAPA with a GF Score™ of 15/100.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kairos Pharma's insider ownership is 10.68%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kairos Pharma's Institutional Ownership is 2.81%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kairos Pharma's Float Percentage Of Total Shares Outstanding is 71.19%.

Kairos Pharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Kairos Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma Insider Ownership Chart

Kairos Pharma Historical Data

The historical data trend for Kairos Pharma can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 40.23 32.68 32.68 32.68 10.01 10.98 10.98 10.68 10.68 10.68
KAPA
15GF Score
Kairos Pharma Ltd KAPA
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 10.68 % mean?
Kairos Pharma (KAPA) has a Insider Ownership of 10.68 % as of Aug. 22, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Kairos Pharma and its competitors.
Is Kairos Pharma's Insider Ownership too high?
Kairos Pharma's current Insider Ownership is 10.68 %. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Insider Ownership compare to ACXP and PULM?
Kairos Pharma's Insider Ownership of 10.68 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current Insider Ownership is 10.68 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Insider Ownership of 10.68 %. The current Insider Ownership is 10.68 %. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Insider Ownership is 10.68 % as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price